Skip to content
Peptigraph home

How to Inject Retatrutide: Sites, Syringes and Steps

Where to inject Retatrutide, which syringe to use, how to read units and the hygiene steps that prevent infection.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 / GIP / glucagon triple agonistUpdated
This is a general guide to subcutaneous injection, not a substitute for being shown by a nurse, pharmacist or doctor.

Injection sites

Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.

  • Belly: at least 2 inches (5 cm) away from the navel.
  • Front and outer thighs.
  • Back of the upper arms, if someone else can reach it.
  • Rotate sites each time and avoid skin that is bruised, scarred or irritated.

Syringe and needle

U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for Retatrutide in studies: not reported in study abstracts (PubMed search, 2 Oct 2026).

How to read an insulin syringe

Step by step

  1. 1Wash your handsUse soap and water, and work on a clean surface.
  2. 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
  3. 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
  4. 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
  5. 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
  6. 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
How to reconstitute a peptide vial

How retatrutide was given in trials: once weekly under the skin

In the phase 3 obesity trial (TRIUMPH-1), retatrutide was given as a once-weekly subcutaneous injection for 80 weeks against placebo.[9]

The registry record for the TRIUMPH-3 cardiovascular-disease trial says retatrutide is given subcutaneously (SC).[10]

An earlier 12-week study in type 2 diabetes randomised people to weekly subcutaneous injections of the drug under its code name, LY3437943, versus placebo or dulaglutide.[11]

No label means no official site, pen or vial instructions

Drugs@FDA returned no matches for retatrutide when the record was cached, so no FDA label gives injection sites, vial storage or an in-use time.[12]

Common questions

Where do you inject Retatrutide?

Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.

What syringe is used for Retatrutide?

Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.

How often is Retatrutide injected?

The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.

How do you inject retatrutide?

There is no approved retatrutide product, so no official technique exists. Trial reports describe a once-weekly subcutaneous injection.[9]

Is retatrutide available from compounding pharmacies?

FDA says no: it cannot be used in compounding under federal law.[13]

How long does retatrutide stay in the body?

Only one human estimate appears in the cached trial abstracts: about 6 days, from the early study in people with type 2 diabetes.[11]

Can retatrutide be injected in the stomach?

The trial abstracts describe a weekly subcutaneous injection and do not name the body site. No retatrutide label exists to list abdomen or any other injection site.[9]

More on Retatrutide

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (Jastreboff AM et al.)New England Journal of Medicine · 2023PMID 37366315Accessed 2 Oct 2026
  4. 4PubMed search: retatrutide[tiab] OR LY3437943[tiab] (197 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (96 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (obesity[tiab] OR diabetes[tiab] OR liver[tiab] OR osteoarthritis[tiab]) AND "Clinical Trial"[pt] (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (SYNCHRONIZE[tiab] OR TRIUMPH[tiab] OR GLORY[tiab] OR DREAMS[tiab]) AND (survodutide[tiab] OR retatrutide[tiab] OR mazdutide[tiab]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.The New England journal of medicine · 2026PMID 42814954Accessed 2 Oct 2026
  10. 10A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular DiseaseClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  11. 11LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
  12. 12Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  13. 13Official web pageOfficial web page · web page

Found an error? Report a correction.